West Pharmaceutical price target lowered to $285 from $355 at BofA

BofA lowered the firm’s price target on West Pharmaceutical (WST) to $285 from $355 and keeps a Buy rating on the shares after the company offered FY25 adjusted EPS guidance that was significantly below expectations. While the firm does think the setback is “disappointing and requires a serious re-evaluation of the business visibility and year-to-year consistency,” it doesn’t believe there’s any real change in the 7%-9% long-range plan, so BofA reiterates a Buy rating.